Shail Mehta, MD
Pulmonary Disease · Saint Louis, MONPI 1124281647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Insmed, Inc. accounts for 97.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $210 and has fallen 65.1% since, to $73 in 2025. That places this record below the midpoint for pulmonary disease clinicians in MO, where the typical reported total is $1,482.
Across 11 payments — averaging $42.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$451
- Takeda Pharmaceuticals U.S.A., Inc.$14
Across 268 payments — averaging $1234.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$159K
- Insmed, Inc.$134K
- Verona Pharma, Inc.$19K
- Redhill Biopharma Inc.$16K
- Boehringer Ingelheim International GmbH$3K
What the payments were for
- Food & beverage$465100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 10 | $451 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$123
How this compares
$465 in reported general payments places this provider in the 30th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 14 | $220,972 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $200,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 119 | $99,501 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 142 | $72,841 |
| Dupixent PenDupilumab | 11 | $48,696 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $30,390 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $19,994 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,865 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $12,553 |
| Rifabutin | 25 | $10,959 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $8,167 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,375 |
| Ethambutol Hcl | 99 | $5,054 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $4,917 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $4,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $451 | $200,57414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.